Johnson & Johnson China
Johnson & Johnson China is the China subsidiary of NYSE-listed Johnson & Johnson, operating innovative pharmaceuticals (Xian Janssen), medical technology devices, and vision care products. It serves hospitals, healthcare professionals, and Chinese consumers through three wholly-owned operating subsidiaries under a Shanghai holding entity.
- Company typePublic
- Founded1985
- Headquarters上海
- Headcount1,001–5,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Johnson & Johnson China does
Johnson & Johnson China (强生中国) is a wholly-owned operating subsidiary of Johnson & Johnson (NYSE: JNJ), the global healthcare conglomerate founded in 1886 in the United States. The China presence dates to 1985 with the establishment of Xian Janssen Pharmaceutical (西安杨森制药). The company operates three core business segments under the legal holding 强生（中国）投资有限公司 in Shanghai: Innovative Pharmaceuticals (Xian Janssen covering hematology, immunology, oncology, infectious diseases, psychiatry, neurology, dermatology); Medical Technology (强生医疗科技 covering minimally invasive and open surgery, electrophysiology, orthopedics, plastic surgery, and infection prevention); and Vision Care (强生视力健 covering Acuvue contact lenses and ocular health). It operates via three core operating subsidiaries: Xian Janssen (pharma), J&J Medical Devices (Shanghai), and J&J Vision Care Trading (Shanghai), with a manufacturing facility in Xi'an and offices in Shanghai.
Its portfolio includes branded, regulatory-protected products such as HARMONIC® 7s ultrasonic scalpels (manufactured in China since 2025), SURGICEL® absorbable hemostatic particles (approved via China's National Medical Device Innovation Green Channel), ETHICON4000 3D-stapling endoscopic staplers (Asia debut in China 2025), and the Allura (傲诺拉) high-end breast implant line, alongside vision products from the J&J Vision Care business. Go-to-market combines enterprise field sales to hospitals and healthcare institutions for medical technology and pharmaceutical products, plus consumer/retail channels for personal health products. The company also maintains an extensive medical professional education network of 26 institutes that train more than 125,000 healthcare professionals annually, creating professional ecosystem engagement.
Revenue mechanics consist of hardware/device unit sales for medical technology, prescription pharmaceutical sales for Xian Janssen, and consumer product sales for vision care and personal health. China-specific revenue is not separately disclosed by the parent. Recent strategic emphasis is on local manufacturing (China-made HARMONIC 7s), AI-augmented solutions (AFib early detection partnership with Apple on wearables; AI-enabled vision diagnostics partnership with 星创视界/宝岛眼镜), deepening neurointervention localization via the 2026 strategic cooperation with 畅医达, and expanding the innovation ecosystem into the Boao Lecheng International Medical Tourism Pilot Zone.
Johnson & Johnson China firmographics
Firmographics- Name
- Johnson & Johnson China
- Legal name
- 强生（中国）投资有限公司 (Johnson & Johnson (China) Investment Co., Ltd.)
- Website
- https://jnj.com.cn
- Company type
- Public
- Founded year
- 1985
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Johnson & Johnson China is the China subsidiary of NYSE-listed Johnson & Johnson, operating innovative pharmaceuticals (Xian Janssen), medical technology devices, and vision care products. It serves hospitals, healthcare professionals, and Chinese consumers through three wholly-owned operating subsidiaries under a Shanghai holding entity.
- Ownership category
- akta.pro rank
Johnson & Johnson China industry classification
Industry- Product category
- Pharmaceuticals and Medical Devices
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Dermatology Specialty Pharmaceuticals (HLAIACAL), Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
Keywords
Where Johnson & Johnson China is headquartered
LocationHeadquarters
- HQ city
- 上海
Offices4 records
Markets served
Johnson & Johnson China business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- 创新制药: 强生一直致力于引进和生产高质量的创新产品来满足不断增长的医药卫生需求，产品覆盖血液、免疫、实体肿瘤、传染病、精神科、神经科等领域
- 医疗器材: 强生医疗中国主要产品为用于微创及开放性手术、电生理学、骨科、整形等领域的医疗器材
- 消费品和个人健康: 强生在消费品和个人健康领域的投资与创新
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Johnson & Johnson China product offering
Product offeringCore offering
Johnson & Johnson China operates a diversified healthcare business in China through three core segments: Innovative Pharmaceuticals (via Xian Janssen), Medical Technology/Medical Devices, and Consumer Health/Personal Care. It develops, manufactures, and commercializes prescription pharmaceuticals across hematology, immunology, oncology, infectious diseases, psychiatry, and neurology; medical devices including surgical staplers, ultrasonic scalpels, hemostatic agents, electrophysiology and orthopedic products; and consumer health products such as contact lenses and breast implants.
Product overview
Johnson & Johnson China operates as a diversified healthcare company with two core business segments: Innovative Pharmaceuticals (创新制药) and Medical Technology (医疗科技). The pharmaceutical business covers hematology, immunology, oncology, infectious diseases, psychiatry, neurology, and dermatology. The medical technology segment provides innovative products for minimally invasive and open surgeries (including wound closure, staplers, ultrasonic scalpels, and absorbable hemostatic gauze), electrophysiology, orthopedics, plastic surgery, and infection prevention. Key branded products include HARMONIC® 7s ultrasonic scalpel (Made in China), SURGICEL® hemostatic materials, 傲诺拉 breast implants, and ETHICON4000 staplers. The company also operates subsidiaries including Xian Janssen Pharmaceutical, J&J Medical Devices China, and Johnson & Johnson Vision Care China.
Differentiator
Problem solved
Functional benefit
Brands
- 傲诺拉 (ALLURA): High-end breast implant brand celebrating 10th anniversary in China
- 西安杨森 (Xian Janssen)
- SURGICEL (速即纱)
- HARMONIC (超声刀)
- ETHICON
- 强生全视 (Johnson & Johnson Vision)
Products and services
- SURGICEL® (速即纱) Absorbable Hemostatic Particles Revolutionary innovative hemostatic product approved via China's National Medical Device Innovation Green Channel; designed to control bleeding during surgical procedures for healthcare professionals and patients.
- HARMONIC® 7s Ultrasonic Scalpel China-made (中国智造) ultrasonic scalpel produced by Johnson & Johnson MedTech China for use in surgical procedures, serving Chinese patients with localized innovation.
- 傲诺拉星钻 (ALLURA Star Diamond) Breast Implants High-end breast implant product under Johnson & Johnson MedTech's ALLURA brand, launched in China celebrating the brand's 10th anniversary; positions technology-empowered natural aesthetics.
- ETHICON4000 Endoscopic Stapler Johnson & Johnson global first 3D stereoscopic stapling technology endoscopic stapler, Asia debut landing in China; opens a new era of minimally invasive innovation.
- Catalys Femtosecond Laser Eye Treatment System Johnson & Johnson Vision's femtosecond laser eye treatment system used for cataract surgery, advancing global medical innovation accessibility through charity programs in Boao.
- 3D Visualization and Magnetic Navigation Dual-Location Electrophysiology Cardiac Surgery Technology Johnson & Johnson MedTech's full-procedure 3D visualization and magnetic-electrical dual-location electrophysiology cardiac surgery technology applied for the first time in a Chinese hospital.
- Innovative Pharmaceuticals Portfolio Pharmaceutical products covering hematology (e.g., multiple myeloma), immunology (e.g., rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis), solid tumors (e.g., prostate cancer), infectious diseases (e.g., HIV, hepatitis, tuberculosis), psychiatry (e.g., schizophrenia), neurology (e.g., depression), colds/cough/fever/digestive, and dermatology/allergies.
Quantifiable outcome
- 强生连续第四次在药品可及性指数排行榜中名列前茅
- +2 more outcomes
Companies that use Johnson & Johnson China
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Johnson & Johnson China technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability7 records
Feature4 records
Johnson & Johnson China partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered 核心战略, 重要合作 and 重要收购.
- 畅医达核心战略强生医疗科技签署战略合作协议，深化神经介入本土创新布局。与畅医达合作再升级，加速创新颅内介入解决方案惠及中国患者
- 星创视界（宝岛眼镜）重要合作强生视力健与星创视界（宝岛眼镜）宣布全新战略合作，开启AI赋能智慧诊断创新服务新篇章，呵护视觉健康
- 苹果 (Apple)重要合作强生与苹果合作评估可穿戴设备对AFib早期识别的影响，从而改善诊断和治疗效果。多达30%的AFib病例在直到出现危及生命的并发症时才能得以确诊
- 爱可泰隆 (Actelion)重要收购2017年强生收购瑞士生物技术公司爱可泰隆（Actelion），为强生带来了世界一流的颠覆性医药产品组合，帮助解决肺动脉高压（PAH）患者的健康需求问题
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Johnson & Johnson China competitors and assessment
Company assessmentDirect peers
- Eli Lilly China: Eli Lilly China is a direct peer in branded specialty pharmaceuticals (oncology, immunology, diabetes, neuroscience), pursuing a comparable tier-1 hospital specialty-care strategy and increasingly competing with Xian Janssen for hospital formulary listings.
- AstraZeneca China: AstraZeneca China competes with J&J China across oncology, respiratory, and CV specialty pharma, and has aggressively scaled localized manufacturing and AI-enabled healthcare initiatives in China comparable to J&J's strategy.
- Abbott China: Abbott's China entity competes directly with J&J Medical Technology in medtech categories (cardiovascular, electrophysiology, diagnostics, vision) and runs a comparable mix of enterprise hospital sales plus consumer channels.
- Medtronic China: Medtronic China competes directly with J&J MedTech in surgical devices, electrophysiology, and orthopedic categories, and shares a similar enterprise hospital sales model and exposure to VBP-driven price compression.
- Bayer China: Bayer China competes with J&J China across specialty pharma (cardiology, oncology, women's health) and consumer health (OTC, diagnostics), with comparable hospital-channel sales infrastructure and NRDL exposure.
- Roche China (Roche Diagnostics + Roche Pharma): Roche China is a direct peer in specialty oncology, immunology and diagnostics-driven pharma/medtech, mirroring J&J China's diversified pharma + medtech footprint with comparable tier-1 hospital sales coverage.
- Sanofi China: Sanofi China is a direct peer in specialty pharma (immunology, rare disease, vaccines) and consumer health, with similar NRDL exposure and a comparable mix of branded prescription and OTC portfolios sold through Chinese hospitals and pharmacies.
- Merck Sharp & Dohme (MSD) China: MSD China is a direct peer in oncology, vaccines and specialty pharmaceuticals, with overlapping hospital-channel GTM and similar exposure to NRDL pricing negotiations in China.
- Novartis China: Novartis China competes directly with J&J's Xian Janssen in branded specialty pharmaceuticals (cardiology, oncology, immunology, neurology) and operates a similar hospital-enterprise sales motion in tier-1 and tier-2 Chinese cities.
- Pfizer China: Pfizer's China entity competes head-to-head with J&J China in branded specialty pharmaceuticals (oncology, vaccines, CNS, immunology) and operates a similar hospital-channel commercial model with localized manufacturing and clinical-education infrastructure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Johnson & Johnson China social profiles
Digital presenceJohnson & Johnson China compliance and trust
Trust signalCompliance2 records
Johnson & Johnson China financial estimates
Financial estimateRevenue estimate
Valuation estimate
Johnson & Johnson China leadership team
Management profileNumber of profiles
Profiles6 records
Johnson & Johnson China subsidiaries and ownership
Company hierarchySubsidiaries3 records
Johnson & Johnson China funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Johnson & Johnson China M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Johnson & Johnson China
What does Johnson & Johnson China do?
Johnson & Johnson China operates a diversified healthcare business in China through three core segments: Innovative Pharmaceuticals (via Xian Janssen), Medical Technology/Medical Devices, and Consumer Health/Personal Care. It develops, manufactures, and commercializes prescription pharmaceuticals across hematology, immunology, oncology, infectious diseases, psychiatry, and neurology; medical devices including surgical staplers, ultrasonic scalpels, hemostatic agents, electrophysiology and orthopedic products; and consumer health products such as contact lenses and breast implants.
Is Johnson & Johnson China a public or private company?
Johnson & Johnson China is a public company. It is classified as public and is currently operating.
When was Johnson & Johnson China founded?
Johnson & Johnson China was founded in 1985. It employs 1,001 to 5,000 people.
Where is Johnson & Johnson China based?
Johnson & Johnson China is headquartered in 上海.
How does Johnson & Johnson China make money?
Three revenue lines are on record. 创新制药 is the primary driver. The others are 医疗器材 and 消费品和个人健康.
Who are Johnson & Johnson China's main competitors?
Direct peers on record are Eli Lilly China, AstraZeneca China, Abbott China, Medtronic China, Bayer China, Roche China (Roche Diagnostics + Roche Pharma), Sanofi China, Merck Sharp & Dohme (MSD) China, Novartis China and Pfizer China.
Does Johnson & Johnson China have an API?
No public API is recorded for Johnson & Johnson China.
What industry is Johnson & Johnson China in?
Johnson & Johnson China's product category is Pharmaceuticals and Medical Devices. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 3841.